Stability analysis of a mathematical model for glioma-immune interaction under optimal therapy

From MaRDI portal
Publication:2422280

DOI10.1515/ijnsns-2017-0206zbMath1464.92129OpenAlexW2921067007WikidataQ128219045 ScholiaQ128219045MaRDI QIDQ2422280

Subhas Khajanchi

Publication date: 19 June 2019

Published in: International Journal of Nonlinear Sciences and Numerical Simulation (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1515/ijnsns-2017-0206




Related Items (17)

The impact of distributed time delay in a tumor-immune interaction systemThe impact of immunotherapy on a glioma immune interaction modelPhase-specific cancer-immune model considering acquired resistance to therapeutic agentsAn optimal control problem of immuno-chemotherapy in presence of gene therapyA tumor-Immune interaction model with the effect of impulse therapyThe role of tumor activation and inhibition with saturation effects in a mathematical model of tumor and immune system interactions undergoing oncolytic viral therapyMultiple bifurcations in a mathematical model of glioma-immune interactionOPTIMAL TREATMENT STRATEGIES USING DENDRITIC CELL VACCINATION FOR A TUMOR MODEL WITH PARAMETER IDENTIFIABILITYOptimal control for dengue eradication program under the media awareness effectRich dynamics of a predator-prey system with different kinds of functional responsesThe impact of the media awareness and optimal strategy on the prevalence of tuberculosisGlioma invasion and its interplay with nervous tissue and therapy: a multiscale modelChaotic dynamics of a delayed tumor–immune interaction modelA mathematical analysis of a tuberculosis epidemic model with two treatments and exogenous re-infectionIs the Allee effect relevant to stochastic cancer model?Optimal control and pattern formation for a haptotaxis model of solid tumor invasionOn chaos of discrete time fractional order host-immune-tumor cells interaction model



Cites Work


This page was built for publication: Stability analysis of a mathematical model for glioma-immune interaction under optimal therapy